Journal of Clinical Oncology
Articles in this Issue
Effect of cDC2 licensing by CCL5 <sup>+</sup> Th1 cells following BCL9/BCL9L inhibition on CD8 <sup>+</sup> T cell cross-priming for enhanced anti-tumor responses.
e16255 Background: Hepatocellular carcinoma (HCC) exhibits limited response to immune checkpoint blockade (ICB) therapy, highlighting the need to further...
Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.
11121 Background: The phase 3 TALAPRO-2 study showed a statistically significant improvement in radiographic progression-free survival for TALA + ENZA vs...
Teclistamab in relapsed/refractory systemic AL amyloidosis.
7562 Background: Systemic light chain amyloidosis (AL) is clonal plasma cell disorder characterized by the deposition of fibrils derived from immunoglobul...
Reliable detection of Merkel cell polyomavirus in Merkel cell carcinoma by whole exome next-generation sequencing.
e15071 Background: Studies indicate that Merkel cell polyomavirus (MCPyV) infection is a causative factor for the development of virus-positive Merkel cel...
Social factors and severity of phenotypic frailty in the Elevate longitudinal cohort of older adults with early-stage breast cancer.
e13847 Background: Phenotypic frailty is a clear risk factor for higher morbidity and mortality in older breast cancer patients. How social factors may be...
Artificial intelligence versus radiologist interpretation in predicting treatment response in lung cancer: A systematic review and meta-analysis.
e23192 Background: Predicting treatment response in lung cancer is vital for optimizing outcomes. The emergence of artificial intelligence (AI) has shown...
Sexuality and age: Functioning and quality of life (QoL) in prostate cancer (PC) patients after surgery.
e17131 Background: QoL after radical prostatectomy (RP) may impact sexual functioning, with possible differences among age groups. Care management and abi...
Myocarditis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A multicenter study.
e20626 Background: Immune checkpoint inhibitors (ICIs) have improved survival in patients with lung cancer; however, their association with immune-related...
Volume and acuity trends in geriatric patients with cancer: Insights from a comprehensive cancer center.
e13852 Background: The risk of cancer increases with age, and with the continuous advancement of the use of novel cancer therapies and improved survival o...
Value of tumor mutational burden as a prognostic factor in patients with non-small cell lung carcinoma.
e20043 Background: Recently, the use of next generation sequencing (NGS) has increased drastically in the treatment of non-small cell lung cancer (NSCLC),...
Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated response and surgical results from a single-arm, phase 2 clinical trial.
e16016 Background: Clinical evidence of conversion therapy for unresectable GC/GEJC is limited. We have reported the encouraging results of the ongoing op...
Earlier brain tumor detection: Assessing the impact on survival, recurrence, inpatient length of stay and neurological deficit.
e23268 Background: Brain tumors commonly present in an emergency setting, but the majority of patients diagnosed with a brain tumor will have had one or m...
DAILY: A prospective single arm study evaluating the impact of vitamin D, aspirin, exercise, and diet in colorectal cancer patients with ctDNA-defined minimal residual disease.
e15534 Background: The successful utilization of circulating tumor DNA (ctDNA) for the identification of micrometastatic disease has fueled the exploratio...
Cosiporfin sodium (DVDMS)-mediated photodynamic therapy (PDT) versus treatment of physician’s choice (TPC) in patients (pts) with advanced esophageal cancer (aEC): A phase III, randomized, open-label, multicenter trial.
4016 Background: Challenges persist in the treatment of aEC, particularly for pts with esophageal stenosis and dysphagia, conditions that deteriorate the...
Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.
4517 Background: Sasanlimab in combination with BCG (induction [IND] and maintenance [MNT]) significantly improved investigator (INV)-assessed EFS vs BCG...
Real-world effectiveness and healthcare utilization of nivolumab for recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC): A real-world population-based study.
e18040 Background: Nivolumab was the first immunotherapy to have shown efficacy in platinum-resistant recurrent and/or metastatic squamous cell carcinoma...
Insurance coverage of germline genetic testing for ovarian, pancreatic, and early-onset colorectal, endometrial, and breast cancers, stratified by self-reported race and ethnicity.
11080 Background: Universal germline genetic testing (GGT) for patients with ovarian (OV), pancreatic (PANC), and early-onset colorectal, endometrial canc...
Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC).
8538 Background: Subsets of NSCLC carry alterations in the human epidermal growth factor receptor 2 (HER2) gene such as mutations (mt), amplification (amp...
A multicenter, randomized, global phase 3 study to assess the efficacy and safety of intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as monotherapy compared with standard of care systemic chemotherapy in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas (STS; INVINCIBLE-3).
TPS11588 Background: Soft tissue sarcomas (STS) are a rare and diverse set of tumors. Systemic chemotherapy provides limited benefit for metastatic diseas...
Use of artificial intelligence-powered spatial analysis of tumor microenvironment to predict the prognosis in resected gallbladder cancer.
4137 Background: Gallbladder cancer (GBC) is a highly lethal disease with a lack of reliable biomarkers. The tumor microenvironment (TME) is closely assoc...
Characterizing functional connectivity in brain tumor patients.
2041 Background: Brain tumors (affecting 25,500 individuals in the US alone) cause unique changes to neural function and connectivity resulting in impairm...
Analytical validation of EPISEEK, an epigenomic blood-based assay for multicancer detection.
3144 Background: Early cancer detection significantly improves treatment outcomes and survival rates. However, cancer screening faces key challenges: (1)...
Real-world analysis of 2IR immune response score in histologic subtype urothelial carcinoma (hsUC).
4568 Background: The 2IR immune response score was initially developed using bulk RNA sequencing of pre-treatment tissue from ImVigor 210 and CheckMate 27...
Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
8599 Background: EVOKE-01 (NCT05089734) assessed the efficacy and safety of SG vs docetaxel in pts with mNSCLC that progressed after platinum-based chemot...
The association of obesity in hospitalized pancreatic cancer patients: A nationwide analysis.
e16435 Background: Pancreatic cancer is the 10th most common cancer among males and the 8th most common cancer for females in the United state. Obesity is...